BioStock: BiBBInstruments comments on its Q3 report

In this year’s Q3 report, it is clear that cancer diagnostic company BiBBInstruments is getting closer to obtaining MDR certification, which is to be followed by further clinical evaluation of EndoDrill, primarily in pancreatic cancer. The clinical interest is really high, and doctors are impatiently waiting to use the company’s instrument. BioStock contacted CEO Fredrik Lindblad to get his comment based on the report.

Read the article at biostock.se:

https://www.biostock.se/en/2022/11/bibbinstruments-comments-on-its-q3-report/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/